"Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer"
作者全名："Zhang, Q.; Wang, J.; Ouyang, Q.; Wang, X.; Lin, D.; Wang, J.; Gan, L.; Ouyang, Z.; Xu, T.; Liu, Y.; Lv, Y."
作者地址："[Zhang, Q.; Wang, J.] Harbin Med Univ, Oncol, Canc Hosp, Harbin, Peoples R China; [Ouyang, Q.] Hunan Canc Hosp, Oncol, Changsha, Peoples R China; [Wang, X.] Zhejiang Canc Hosp, Oncol, Canc Res Inst, Hangzhou, Peoples R China; [Lin, D.] Sun Yat Sen Univ, Oncol, Jiang Men Cent Hosp, Affiliated Jiangmen Hosp, Jiangmen, Peoples R China; [Wang, J.] Tumor Hosp Linyi City, Oncol, Linyi, Peoples R China; [Gan, L.] Chongqing Med Univ, Oncol, Affiliated Hosp 1, Chongqing, Peoples R China; [Ouyang, Z.] Xiamen Univ, Oncol, Affiliated Hosp 1, Xiamen, Peoples R China; [Xu, T.] Jiangsu Alphamab Biopharmaceut Co Ltd, Suzhou, Peoples R China; [Liu, Y.] Jiangsu Alphamab Biopharmaceut Co Ltd, Med, Suzhou, Peoples R China; [Lv, Y.] Jiangsu Alphamab Biopharmaceut Co Ltd, Biostat, Suzhou, Peoples R China"
通信作者：
来源：ANNALS OF ONCOLOGY
ESI学科分类：CLINICAL MEDICINE
WOS号：WOS:001087480200407
JCR分区：Q1
影响因子：50.5
年份：2023
卷号：34
期号：
开始页：S358
结束页：S358
文献类型：Meeting Abstract
关键词：
摘要：
基金机构：Jiangsu Alphamab Biopharmaceuticals Co. Ltd.
基金资助正文：Jiangsu Alphamab Biopharmaceuticals Co. Ltd.
